"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

Masses under 2 cm are typically managed with active surveillance. Options for masses that are 2 to 4 cm include ablation (eg, cryotherapy, radiofrequency ablation) and surgical approaches. Kidney ...

Current 2025 guidelines recommend ADT with intensification. Multiple intensification options include abiraterone, darolutamide, and docetaxel. Key clinical trials include ARANOTE, ARASENS, and TITAN.

Cytoreductive nephrectomy (CN) remains vital in mRCC management, with immune checkpoint inhibitors (ICI) reshaping treatment strategies and patient selection criteria. The SCREEN score offers superior ...

"There was a significant increase in overall fatigue after performing flexible ureteroscopy," says Sarah Razavi, MD. “This was a multi-institutional study, and the goal was to evaluate the urologist ...

Panelist discusses how hospitals benefit from adopting aqua ablation therapy by improving surgical efficiency, reducing turnover times, enabling outpatient procedures, and providing a highly effective ...

Black men are significantly underrepresented in prostate cancer clinical trials (<5% in most studies). Many trials fail to provide race-specific data. The ARANOTE study achieved 10% representation of ...

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes. Dr Shore presented data demonstrating that ...

The first successful human bladder transplant was performed by USC and UCLA surgeons, marking a significant medical milestone. The patient, previously on dialysis, showed immediate improvement ...

Dr Shore explained the rationale for examining the ultra-low PSA threshold of <0.02 ng/mL in the ARANOTE trial. The discussion highlighted the historical relevance of low PSA levels in predicting ...

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.